Axogen, Inc. (AXGN) fair value analysis
Nasdaq · Updated 2026-09-07
Axogen, Inc. is a healthcare company that develops and markets surgical solutions for peripheral nerve injuries, including nerve grafts and related products used in surgical repair procedures. The company operates primarily in the United States and serves hospitals, surgical centers, and healthcare providers that treat patients requiring nerve reconstruction.
Valuation status
Awaiting full valuationAXGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $45.73
- Sector
- Healthcare
- 12-month range
- $17.87–$45.73
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for AXGN
- Our model validated 4 trailing price-to-earnings windows for AXGN, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $17.87–$45.73.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AXGN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent AXGN news
TickrTrends' derived news-sentiment signal for AXGN is currently leaning positive, computed from recent coverage.
- Axogen (AXGN) Director Joseph Tyndall Sells 3,500 Shares (gurufocus.com, 2026-09-05)
TickrTrends take: Axogen operates in the Healthcare sector, where insider trading activity can serve as a signal for valuation assessment purposes. The sale of shares by director Joseph Tyndall represents a transaction that valuation analysts typically monitor alongside fundamental metrics when a company's full valuation picture remains under review. Given that TickrTrends is currently awaiting full valuation for AXGN, observers should consider how insider trading patterns may inform the broader evaluation of the company's financial position and management's confidence levels. - Axogen Inc (AXGN) Shares Fall 3.2% -- What GF Score of 64 Tells Investors (gurufocus.com, 2026-09-02)
TickrTrends take: Axogen Inc trades in the Healthcare sector where investors typically scrutinize both operational metrics and valuation multiples to assess fair value. The stock's recent decline coincides with a GF Score of 64, a mid-range assessment that suggests the company merits continued monitoring as TickrTrends awaits completion of its full valuation analysis. For investors focused on valuation context, the combination of sector dynamics and the current scoring indicates that a comprehensive price target assessment remains pending. - Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100 (gurufocus.com, 2026-08-26)
TickrTrends take: Axogen trades in the Healthcare sector while TickrTrends awaits completion of its full valuation analysis on the stock. The recent price movement and GF Score rating suggest investors focused on valuation metrics have differing assessments of the company's worth, highlighting the importance of monitoring how TickrTrends completes its evaluation before drawing conclusions about fair value. Valuation-focused readers should track whether incoming financial data or company developments help clarify the disconnect between current pricing and fundamental value estimates.
What people are saying
Follow the AXGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AXGN stock undervalued?
AXGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is AXGN's TickrTrends verdict?
AXGN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is AXGN overbought or oversold?
AXGN's 14-day RSI is in neutral territory - neither overbought nor oversold.